Dadun Dadun cabecera universidad cabecera biblioteca
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología hepatitis virales > DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista >

Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C
Authors: Gavier, B. (B)
Martinez-Gonzalez, M.A. (Miguel Angel)
Riezu-Boj, J.I. (José Ignacio)
Lasarte, J.J. (Juan José)
Garcia, N. (Nicolás)
Civeira, M.P. (María Pilar)
Prieto, J. (Jesús)
Keywords: Antiviral Agents/therapeutic use
Hepatitis C/therapy
Interferon-alpha/therapeutic use
Viremia/therapy
Issue Date: 1997
Publisher: WB Saunders
Publisher version: http://www.sciencedirect.com/science/article/pii/S0016508597005325
ISSN: 1528-0012
Citation: Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997 Nov;113(5):1647-1653.
Abstract
BACKGROUND & AIMS: In chronic hepatitis C, interferon alfa induces sustained remission in less than 30% of treated patients. The aim of this study is to analyze viral status early after initiation interferon therapy as a predictor of treatment outcome. METHODS: One hundred eighty-one patients with chronic hepatitis C who had been treated with interferon alfa for 12 months (median follow-up, 49 months) were studied. Viremia and aminotransferase levels at the first and third months of therapy as well as 10 pretreatment variables were assessed as potential independent predictors of sustained response to treatment. RESULTS: Sustained response occurred in 51 patients (28%). At month 1 of treatment, viral persistence accurately predicted nonresponse (predictive value, 95.3; 95% confidence interval, 86.0-98.8; P < 0.0001). Independent predictors of sustained response were undetectable viremia at the first month of therapy (P < 0.001), undetectable viremia at the third month (P < 0.001), younger age (P = 0.006), nonsporadic infection (P = 0.012), and higher pretreatment aspartate aminotransferase levels (P = 0.032). In patients who cleared HCV RNA at month 1 of therapy, the predicted probability of sustained response averaged 70% for those younger than 30 years and diminished by 10% for each decade of age. CONCLUSIONS: Failure to clear HCV RNA at month 1 of treatment is strongly and independently associated with a very low probability of a sustained response to interferon.
Permanent link: http://hdl.handle.net/10171/21677
Appears in Collections:DA - Medicina - MPSP -Artículos de revista
DA - CUN - Medicina interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Virología - Artículos de revista
DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista

Files in This Item:
File:  Gastroenterol19971131647.pdf
Description: 
Size:  286,89 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.